Skip to main content
SpringerLink
Log in

Fluvastin therapy affects TAFI concentration in kidney transplant recipients

  • Brief Report
  • Published:
Transplant International

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein, linking coagulation and fibrinolysis. Recently, attention has been drawn to the beneficial effects of statins on haemostasis in kidney patients prone to dyslipidaemia and with a high risk of cardiovascular death. The purpose of this study was to assess whether fluvastatin affects TAFI concentration in renal transplant recipients. We evaluated thrombin–antithrombin (TAT) complexes, prothrombin fragments 1+2, thrombomodulin, plasmin–antiplasmin (PAP) complexes, TAFI, P-selectin, and lipoprotein (a), 1, 2, and 3 months before and after fluvastatin treatment and in normolipaemic kidney transplant recipients and healthy volunteers. Cholesterol and LDL fell significantly as soon as 1 month after treatment had begun and remained lowered during the therapy. TAFI and prothrombin fragments 1+2 decreased significantly after 3 months of fluvastatin administration, whereas P-selectin decreased significantly after 2 months and remained significantly lower after 3 months of this therapy. We can conclude that fluvastatin is an effective hypolipaemic agent that favourably affects haemostasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Locatelli F, Del Vecchio L, Manzoni C (1998) Morbidity and mortality on maintenance hemodialysis. Nephron 80:380–400

    Article  CAS  PubMed  Google Scholar 

  2. US Renal Data System (1999) USRDS 1999 Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, Md

  3. Pirsch JD, D'Alessandro AM, Solinger HW, Knechtle SJ, Reed A, Klayoglu M, Belzer FO (1992) Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 2:238–242

    Google Scholar 

  4. Sweny P, Wheeler DC, Lui SF, Amin NS, Barradas MA, Jeremy JY, Mikhailidis DP, Varghese Z, Fernando ON, Moorhead JF (1989) Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 4:1070–1075

    CAS  PubMed  Google Scholar 

  5. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386–391

    CAS  PubMed  Google Scholar 

  6. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME (1998) A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 273:27176–27181

    CAS  PubMed  Google Scholar 

  7. Bajzar L, Nesheim ME, Morser J, Tracy PB (1998) Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 273:2793–2798

    Article  Google Scholar 

  8. Ambrosi P, Ailaud MF, Habib G, Kreitman B, Metras D, Luccioni R, Bouvenot G, Juhan-Vague I (2000) Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 83:46–48

    CAS  PubMed  Google Scholar 

  9. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada A (1994) Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 75:569–576

    CAS  PubMed  Google Scholar 

  10. Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M (2001) A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 16:1692–1696

    Article  CAS  PubMed  Google Scholar 

  11. van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855–2859

    PubMed  Google Scholar 

  12. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (1996) Coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 62:828–830

    CAS  PubMed  Google Scholar 

  13. Baker LRI, Tucker B, Kovacs IB (1990) Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation 49:905–909

    CAS  PubMed  Google Scholar 

  14. Venrenterghem Y, Roels I, Lerut T, Gruwez J, Michielsen P, Gresele P, Deckmyn H, Colucci M, Arnout J, Vermylen J (1985) Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaver kidney allograft recipients. Lancet:999–1002

  15. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M (2001) Simvastatin affects TAFI and thrombomodulin in CAPD patients. Thromb Haemost 86:900–901

    Google Scholar 

  16. Agewall S, Wikstrand J, Fagerberg B (1998) Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertens 16:537–541

    CAS  PubMed  Google Scholar 

  17. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Woltz M, Schmetter L, Dorner GT (2001) Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 85:47–51

    CAS  PubMed  Google Scholar 

  18. Patrassi GM, Sartori MT, Rigotti P, Di Landro D, Theodoridis P, Fioretti M, Capalbo M, Saggiorato G, Boeri G, Girolami A (1995) Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation 59:1416–1420

    CAS  Google Scholar 

  19. Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495

    CAS  PubMed  Google Scholar 

  20. Johnston GI, Bliss GA, Newman PJ, McEver RP (1990) Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J Biol Chem 265:21381–21385

    CAS  PubMed  Google Scholar 

  21. Blann AD, Lip GYH (1997) Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 128:135–138

    Article  CAS  PubMed  Google Scholar 

  22. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S (1998) Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 31:39–45

    Article  CAS  PubMed  Google Scholar 

  23. Schror K (1990) Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterol lowering agents. Eicosanoids 3:67–73

    CAS  PubMed  Google Scholar 

  24. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M (1996) Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporin A. Transplant Proc 28:1954–1957

    Google Scholar 

  25. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL (1999) Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor. Thromb Res 95:229–234

    Article  CAS  PubMed  Google Scholar 

  26. Goldberg RB, Roth D (1995) A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 76:107A–109A

    Google Scholar 

  27. Loscalzo J (1990) Lipoprotein (a). A unique risk factor for atherothrombotic disease. Arteriosclerosis. 10:672–680

    Google Scholar 

  28. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C (1995) Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups: a review of the literature. Nephron 70:155–165

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Internal Medicine, Medical Academy Bialystok, Zurawia 14, 15-540 Bialystok, Poland

    Jolanta Malyszko, Jacek S. Malyszko & Michal Mysliwiec

Authors
  1. Jolanta Malyszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacek S. Malyszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michal Mysliwiec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacek S. Malyszko.

Additional information

The study was supported in part by a grant from the Polish Research Committee KBN (no. 6 PO 5 8 117 21).

About this article

Cite this article

Malyszko, J., Malyszko, J.S. & Mysliwiec, M. Fluvastin therapy affects TAFI concentration in kidney transplant recipients. Transpl Int 16, 53–57 (2003). https://doi.org/10.1007/s00147-002-0495-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00147-002-0495-9

Keywords

Search

Navigation